High rate of complete remission and upgraded response with weekly maintenance bortezomib post single autologous peripheral stem cell transplant in patients with multiple myeloma. Results of a phase II prospective study

被引：0
|
作者：
Sahebi, F. [1 ]
Krishnan, A. [1 ]
Farol, L. [1 ]
Cai, J. -L. [1 ]
Somlo, G. [1 ]
Popplewell, L. [1 ]
Parker, P. [1 ]
Spielberger, R. [1 ]
Kogut, N. [1 ]
Karanes, C. [1 ]
Ruel, C. [1 ]
Frankel, P. [1 ]
Reburiano, E. [1 ]
Duarte, L. [1 ]
O'Donnell, L. [1 ]
Forman, S. [1 ]
机构：
[1] City Hope Med Ctr, Duarte, CA USA
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [21] A phase I/II study of Xcellerated T cells™ after autologous peripheral blood stem cell transplantation in patients with multiple myeloma.
    Siegel, D
    Vij, R
    Vescio, RA
    Borrello, IM
    Martin, TG
    Berenson, JR
    Ferrand, C
    Janmohamed, F
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2004, 104 (11) : 265A - 265A
  • [22] A phase I/II study of Xcellerated T cells after autologous peripheral blood stem cell transplantation in patients with multiple myeloma.
    Borrello, IM
    Vij, R
    Vescio, RA
    Martin, TG
    Siegel, D
    Berenson, JR
    Janmohamed, F
    Bonyhadi, M
    Berenson, RJ
    Frohlich, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 173S - 173S
  • [23] A phase I/II study of Xcellerated T cells™ after autologous peripheral blood stem cell transplantation in patients with multiple myeloma.
    Vij, R
    Borrello, IM
    Martin, T
    Vescio, R
    Siegel, D
    Bashey, A
    DiPersio, JF
    Berenson, J
    Ferrand, C
    Janmohamed, F
    Yuan, V
    Bouchard, L
    Berenson, RJ
    Bonyhadi, M
    Frohlich, MW
    BLOOD, 2003, 102 (11) : 43A - 43A
  • [24] Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM).
    Thomas, Sheeba K.
    George, Jamie S.
    de Partovi, Claudia M. Morales
    Feng, Lei
    Morphey, Ashley S.
    Becnel, Melody R.
    Kaufman, Gregory P.
    Lee, Hans C.
    Manasanch, Elisabet Esteve
    Patel, Krina K.
    Pasvolsky, Oren
    Ye, Jing Christine
    Amini, Behrang
    Qazilbash, Muzaffar H.
    Bashir, Qaiser
    Crumpton, Brandon N.
    Stafford, Mildred M.
    Johnson, Ralph J., III
    Weber, Donna M.
    Orlowski, Robert Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)
    Thomas, Sheeba K.
    Shah, Jatin J.
    Morphey, Ashley N.
    Lee, Hans C.
    Manasanch, Elisabet E.
    Patel, Krina K.
    Miller, Carla P.
    Phillips, Suzanne
    Crumpton, Brandon N.
    Johnson, Ralph J.
    Feng, Lei
    Iyer, Swaminathan P.
    Amini, Behrang
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD, 2018, 132
  • [26] CANADIAN COST ANALYSIS COMPARING MAINTENANCE THERAPY WITH BORTEZOMIB VERSUS LENALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA POST AUTOLOGOUS STEM CELL TRANSPLANT
    LeBlanc, R.
    Hollmann, S.
    Tay, J.
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2016, 23 (01): : E103 - E113
  • [27] Bortezomib once weekly is well tolerated as maintenance therapy after less than a complete response to high-dose melphalan in patients with multiple myeloma.
    Knop, Stefan
    Hebart, Holger
    Kunzmann, Volker
    Angermund, Ralf
    Einsele, Hermann
    BLOOD, 2006, 108 (11) : 364B - 364B
  • [28] A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma
    Abidi, Muneer H.
    Gul, Zartash
    Lum, Lawrence G.
    Abrams, Judith
    Cronin, Simon
    Ventimiglia, Marie
    Deol, Abhinav
    Ayash, Lois
    Al-Kachimi, Zaid
    Ratanatharathorn, Voravit
    Uberti, Joseph P.
    BLOOD, 2010, 116 (21) : 989 - 989
  • [29] Feasibility and toxicity of maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma
    Sahebi, F
    Somlo, G
    Kogut, NM
    Falk, PM
    Spielberger, R
    Parker, PM
    Krishnan, A
    Frankel, P
    Kosobayashi, N
    Forman, SJ
    BLOOD, 2003, 102 (11) : 984A - 984A
  • [30] SINGLE VERSUS TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MULTIPLE MYELOMA PATIENTS AND ROLE OF SECOND SALVAGE TRANSPLANT: A SINGLE CENTER PROSPECTIVE PHASE II STUDY
    Moreb, J. S.
    Salmasinia, D.
    Leather, H.
    Davis, A.
    Hsu, J. W.
    Wiggins, L.
    Cogle, C. R.
    Chang, M. N.
    Wingard, J. R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S299 - S299
12345